Skip to content
Lupin logo

Lupin

LUPIN NSE
₹2,014.00 +15.20 (+0.76%)
Market Cap
₹92,098 Cr
P/E
17.69
View as Markdown
MCP
Close 20 Nov 2026 ₹2,014.00 1Y +14.40 +0.72%
Start ₹1,999.60

Key Fundamentals

MidcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
29.90%
Debt to Equity
0.26
EPS (TTM)
₹113.88
Book Value
₹525.92
Market Cap
₹92,098 Cr
P/E (TTM)
17.69
P/B
3.83
ROE
28.70%
Dividend Yield
0.90%
EBITDA
₹9,240 Cr
52W High
₹2,529.50
52W Low
₹1,892.90
Day Range
₹1,985.10 – ₹2,014.00
Volume
6,30,830

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

Lupin peer comparison
1,884.9041.254,52,2515.070.85%16.00%20.50%61,63110,987
11,180.5088.262,96,80716.490.27%16.50%22.00%12,1913,363
4,689.5077.801,78,3749.710.82%27.40%15.20%17,4002,099
2,294.6092.521,23,98020.450.04%18.30%17.80%7,8231,332
1,200.0028.631,19,7004.300.08%21.20%21.10%30,3784,303
1,390.2041.441,16,0372.990.57%11.20%13.00%33,0972,760
1,415.0039.451,14,3123.230.92%11.60%15.50%28,1392,855
Lupin (this company)
2,014.0017.6992,0983.830.91%28.70%29.90%30,7465,222
Median 8 companies1,949.4541.351,21,8404.690.70%17.40%19.15%29,2593,109

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

57 Good

Data confidence 100/100

Category scores

Quality
57
Good
Returns, margins, earnings quality 22% weight
Valuation
89
Strong
Cheap vs sector & own history 24% weight
Growth
73
Strong
Sales & profit trajectory 9% weight
Financial Health
48
Average
Solvency, leverage, coverage 9% weight
Momentum
11
Poor
Trend strength, vol-adjusted 12% weight
Ownership
49
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has delivered good profit growth of 37.0% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 17.1%
  • Company's working capital requirements have reduced from 46.4 days to 28.0 days

No weaknesses listed

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish667
OscillatorsBullish162
Moving AveragesNeutral505

Key readings

RSI (14)
53.46
Neutral
MACD (12,26,9)
−5.08
Bullish
SMA (50)
2,012.25
Bullish
SMA (200)
2,230.63
Bearish

As of

Analyst Rating

Based on 35 analysts
BUY43%

15 of 35 analysts rate Buy, 12 Hold, 8 Sell.

As of

BUY
15
43%
HOLD
12
34%
SELL
8
23%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+6.97%
5Y+13.02%
3Y+18.88%
1Y+23.12%
TTM+24.23%

Net profit

Net profit growth by window
10Y+8.96%
5Y+34.25%
3Y+128.64%
1Y+61.98%
TTM+20.13%

Operating cash flow

Operating cash flow growth by window
10YTurned positive
5Y+32.12%
3Y+56.95%
1Y+144.47%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+3.30 pp
5Y+12.26 pp
3Y+18.85 pp
1Y+5.95 pp
TTM+2.81 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹17,367 Cr
Mar 2018₹15,797 Cr
Mar 2019₹14,665 Cr
Mar 2020₹15,375 Cr
Mar 2021₹15,163 Cr
Mar 2022₹16,405 Cr
Mar 2023₹16,642 Cr
Mar 2024₹20,011 Cr
Mar 2025₹22,708 Cr
Mar 2026₹27,958 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹2,565 Cr
Mar 2018₹258 Cr
Mar 2019₹615 Cr
Mar 2020−₹270 Cr
Mar 2021₹1,228 Cr
Mar 2022−₹1,528 Cr
Mar 2023₹448 Cr
Mar 2024₹1,936 Cr
Mar 2025₹3,306 Cr
Mar 2026₹5,355 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹1,642 Cr −22.9% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 19 Nov 2026
AI opinion · based on fundamentals
Risk medium

Lupin Ltd trades at ₹1,998.8 with a market cap of ₹91,403 crore as of 2026-11-19. The company has delivered strong profit growth of 37% CAGR over five years with an ROE of 23.79% and conservative leverage at a debt-to-equity ratio of 0.29, though the stock is down 2% over the past year and sits roughly 21% below its 52-week high of ₹2,529.5.

Bull Case 8
  • Compounded profit growth of 37% CAGR over the last 5 years and 140% over the last 3 years indicates a sharp earnings recovery and expansion cycle
  • ROE of 23.79% and ROCE of 28.42% as of 2026-11-19 reflect efficient capital allocation relative to many Indian pharma peers
  • TTM revenue growth of 24% shows continued top-line momentum, well above the 10-year compounded sales growth rate of 7%
  • Low debt-to-equity ratio of 0.29 provides balance sheet flexibility for R&D investment, acquisitions, or capacity expansion without undue financial risk
  • Working capital days have compressed from 46.4 to 28.0, improving cash conversion and freeing up capital for reinvestment
  • TTM profit growth of 30% on top of already elevated 3-year and 5-year profit CAGRs suggests earnings momentum is still intact
  • Consistent dividend payout of 17.1% with a current dividend yield of 0.91% provides a modest income stream while retaining earnings for growth
  • PE of 17.55x as of 2026-11-19, combined with 30% TTM earnings growth, implies a PEG ratio below 1x on trailing numbers, which some investors view favourably
Bear Case 8
  • The stock has delivered a negative 1-year return of -2%, underperforming broader Indian equity indices and signalling potential near-term sentiment headwinds
  • Current price of ₹1,998.8 is approximately 21% below the 52-week high of ₹2,529.5, indicating a meaningful correction that may reflect changing growth expectations
  • 10-year compounded sales growth of only 7% suggests the recent 24% TTM revenue growth may represent a cyclical peak rather than a sustainable trajectory
  • 10-year compounded profit growth of 10% contrasts sharply with the 3-year figure of 140%, highlighting that much of the recent profit surge may be a recovery from a low base rather than structural improvement
  • 10-year ROE averages only 10% compared to the last year's 29%, raising questions about whether current high-return levels can persist through industry cycles
  • 10-year stock CAGR of just 4% shows that long-term shareholders have seen limited compounding despite recent operational improvement
  • Price-to-book of 3.8x means the market is pricing significant goodwill and intangible value; any earnings miss could trigger a de-rating
  • As a global generics-focused pharma company, Lupin faces regulatory risk from agencies such as the US FDA, where adverse inspection outcomes or pricing pressure could materially impact revenue and margins

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

23h ago

TL;DR: Lupin is executing well on its US generics pipeline, landing two first-to-file exclusivity launches (Raltegravir, Amifampridine) and expanding its biosimilar footprint in Europe. However, a 22% YoY drop in Q2FY27 net profit despite revenue growth signals margin pressure that bears watching. The trend on product launches and approvals is clearly positive, but profitability improvement will be key to sustaining momentum in the near term.

Headwinds 1
  • Q2FY27 net profit drops 22% Nov 3

    Consolidated PAT declined 22% YoY to ₹11,553 mn in Q2FY27, despite 11% YoY revenue growth driven by pharmaceutical sales.

Positives 3
  • Raltegravir US launch with exclusivity Nov 3

    Lupin launched Raltegravir 600 mg tablets in the US as the first-to-file generic, securing 180-day exclusivity for this HIV treatment.

  • US FDA nod for Amifampridine Nov 2

    Received US FDA approval for Amifampridine 10 mg tablets with first-to-file status, eligible for 180 days of shared generic exclusivity.

  • Ranibizumab biosimilar launched in Europe Nov 12

    Partner Sandoz launched Ranluspec, a Ranibizumab biosimilar, across Europe excluding Germany on November 12, 2026.

Neutral 2
  • Akhil Gupta appointed independent director Nov 3

    Akhil Gupta was appointed as Additional Director (Non-Executive, Independent) effective November 3, 2026, with a postal ballot for shareholder approval opening November 17.

  • Brian Savage named Chief Legal Officer Oct 22

    Brian Savage was appointed President and Chief Legal Officer effective October 22, 2026, bringing extensive global pharma legal experience.

Quarterly Results

₹ Cr
LUPIN quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
5,039
5,197
4,961
5,600
5,673
5,768
5,667
6,268
7,048
7,168
7,475
8,277
7,827
Expenses
4,121
4,159
3,964
4,359
4,332
4,412
4,346
4,541
4,706
4,906
4,989
5,827
5,783
Operating Profit
918
1,038
997
1,241
1,340
1,356
1,321
1,727
2,341
2,262
2,486
2,450
2,044
OPM %
18%
20%
20%
22%
24%
24%
23%
28%
33%
32%
33%
30%
26%
Other Income
40
29
29
68
42
54
57
79
90
−312
141
130
127
Interest
81
74
71
68
71
67
89
92
108
115
120
110
106
Depreciation
248
257
457
248
257
271
393
299
317
313
447
453
486
Exceptional Items
—
—
—
—
—
—
—
—
—
—
−131
—
—
PBT
630
736
498
993
1,055
1,071
896
1,416
2,007
1,522
1,928
2,017
1,580
Tax %
21%
16%
26%
19%
19%
20%
13%
14%
26%
22%
24%
30%
27%
Net Profit
495
619
368
806
859
859
782
1,221
1,485
1,181
1,469
1,417
1,155
EPS (₹)
10.76
13.47
7.89
17.58
18.69
18.74
16.92
26.69
32.36
25.73
31.94
30.95
25.26
YoY Sales growth
22
20
12
16
13
11
14
12
24
24
32
32
11

Profit & Loss

₹ Cr
LUPIN profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
12,770
14,256
17,367
15,797
14,665
15,375
15,163
16,405
16,642
20,011
22,708
27,958
30,746
Expenses
9,146
10,564
12,865
12,649
12,104
13,020
12,596
16,187
14,921
16,211
17,430
19,798
21,505
Operating Profit
3,624
3,691
4,502
3,148
2,561
2,355
2,567
219
1,721
3,800
5,278
8,160
9,241
OPM %
28%
26%
26%
20%
17%
15%
17%
1.3%
10%
19%
23%
29%
30%
Other Income
235
184
106
−1,310
91
−134
138
210
151
131
202
523
−45
Interest
10
59
153
204
302
363
141
143
274
312
295
434
450
Depreciation
435
487
912
1,086
846
970
887
1,659
881
1,197
1,169
1,376
1,698
PBT
3,415
3,329
3,543
547
1,503
887
1,676
−1,372
716
2,422
4,015
6,873
7,047
Tax %
28%
32%
28%
53%
59%
130%
27%
10%
38%
20%
18%
22%
—
Net Profit
2,444
2,270
2,565
258
615
−270
1,228
−1,528
448
1,936
3,306
5,355
5,221
EPS (₹)
53.47
50.17
56.63
5.56
13.40
−5.95
26.81
−33.62
9.45
42.01
71.88
116.65
113.88
Div. Payout %
14%
15%
13%
90%
37%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
24%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
42%
19%
17%
15%
—
Sales growth
13
12
22
−9
−7
5
−1
8
1
20
13
23
24

Balance Sheet

₹ Cr
LUPIN balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
90
90
90
90
90
91
91
91
91
91
91
91
91
Reserves
8,784
11,073
13,407
13,487
13,652
12,446
13,712
12,062
12,374
14,199
17,112
22,357
23,959
Borrowings
537
7,178
7,966
7,143
8,496
6,305
4,783
4,158
4,542
2,922
5,448
6,616
6,180
Other Liabilities
3,642
3,957
4,749
5,300
5,423
5,968
4,844
5,340
5,794
6,539
6,327
9,082
9,680
Total Liabilities
13,054
22,298
26,212
26,020
27,661
24,810
23,430
21,651
22,800
23,751
28,978
38,146
39,911
Fixed Assets
4,368
8,717
11,033
10,362
11,087
7,938
7,881
7,382
8,355
8,878
9,719
10,994
13,332
CWIP
576
2,702
2,133
2,598
1,640
940
1,066
1,146
1,238
773
517
1,016
931
Investments
1,658
16
2,136
262
2,295
2,374
2,455
900
517
1,075
1,146
3,670
4,456
Other Assets
6,451
10,862
10,910
12,798
12,639
13,557
12,028
12,224
12,690
13,026
17,596
22,466
21,191
Total Assets
13,054
22,298
26,212
26,020
27,661
24,810
23,430
21,651
22,800
23,751
28,978
38,146
39,911

Cash Flow

₹ Cr
LUPIN cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
2,733
−382
4,114
1,751
1,666
1,469
1,822
367
1,897
3,648
3,000
7,334
Investing
−1,034
−6,769
−2,527
470
−3,282
1,107
−1,240
1,292
−1,287
−1,712
−4,172
−3,865
Financing
−197
5,836
433
−1,492
744
−891
−1,885
−1,572
−337
−2,184
1,732
−846
Net Cash Flow
1,502
−1,315
2,019
729
−872
1,685
−1,303
87
273
−248
560
2,624
Free Cash Flow
1,865
−6,164
1,513
261
706
798
1,150
−531
436
2,732
1,347
5,527
CFO/EBITDA
101
21
117
73
102
84
99
146
124
105
74
105

Ratios

LUPIN financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
76
116
91
120
128
129
108
95
98
86
88
86
Inventory Days
220
276
266
253
283
232
279
261
242
272
292
303
Days Payable
172
168
189
178
184
162
137
129
136
163
158
208
Cash Conversion Cycle
124
225
167
195
227
199
249
227
204
195
223
181
Working Capital Days
56
102
63
126
115
33
34
45
32
53
58
28
ROCE %
40%
24%
19%
10%
10%
9%
9%
−7%
6%
16%
21%
30%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Lupin insights

72 extracted metrics across FY00–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 46.84%
  • DIIs 23.78%
  • FIIs 23.28%
  • Public 5.13%
  • Others 0.96%

No promoter shares pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Lupin

What does Lupin Ltd do?
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC)…
Where is Lupin Ltd (LUPIN) listed?
Lupin Ltd trades as LUPIN on the NSE and under code 500257 on the BSE.
Which sector does Lupin Ltd belong to?
Lupin Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Lupin Ltd?
Lupin Ltd has a market capitalisation of ₹92,098 Cr as of 20 Nov 2026, which places it in the Midcap band.
What is the PE ratio of Lupin Ltd?
Lupin Ltd trades at a PE ratio of 17.69 as of 20 Nov 2026, on earnings per share of ₹113.88, against a book value of ₹525.92 per share.
What is the 52-week high and low of Lupin Ltd?
Over the last 52 weeks Lupin Ltd has traded between ₹1,892.9 and ₹2,529.5 as of 20 Nov 2026.
Does Lupin Ltd pay dividends?
Lupin Ltd has a dividend yield of 0.90%.
What is the Return on Equity (ROE) of Lupin Ltd?
Lupin Ltd reported a return on equity of 28.70%. Its debt-to-equity ratio is 0.26.

Company Information

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Website lupin.com
CEO Ms. Vinita D. Gupta
Employees 24,006
Listed 10 Sep 2001
Face Value ₹2
Shares Outstanding 45,72,89,972

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LUPIN.md for Lupin Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More